Last reviewed · How we verify
Lobeglitazone 0.5 mg
At a glance
| Generic name | Lobeglitazone 0.5 mg |
|---|---|
| Also known as | Duvie 0.5 mg |
| Sponsor | Seoul National University Bundang Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors (PHASE4)
- Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (PHASE4)
- Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie (PHASE4)
- Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 (PHASE1)
- Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients (PHASE4)
- Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin (PHASE1)
- Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers (PHASE1)
- A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lobeglitazone 0.5 mg CI brief — competitive landscape report
- Lobeglitazone 0.5 mg updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI